These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27928736)

  • 41. New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
    Hsu PI
    J Gastroenterol Hepatol; 2012 Apr; 27(4):654-61. PubMed ID: 22283743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
    Raju NC; Eikelboom JW; Hirsh J
    Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents.
    Uchida Y; Mori F; Ogawa H; Takagi A; Hagiwara N
    J Cardiol; 2010 May; 55(3):362-9. PubMed ID: 20350510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
    Lam S; Tran T
    Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiplatelet therapy: controversial aspects.
    Coccheri S
    Thromb Res; 2012 Mar; 129(3):225-9. PubMed ID: 22119155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
    Alcocer F; Novak Z; Combs BR; Lowman B; Passman MA; Mujib M; Jordan WD
    J Vasc Surg; 2014 Apr; 59(4):950-5. PubMed ID: 24491238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
    Krane V; Wanner C
    Am J Kidney Dis; 2005 Mar; 45(3):607-9. PubMed ID: 15754285
    [No Abstract]   [Full Text] [Related]  

  • 50. Novel Antiplatelet Agents in Cardiovascular Disease.
    Tscharre M; Michelson AD; Gremmel T
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):191-200. PubMed ID: 31960728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Platelet Responses in Cardiovascular Disease: Sex-Related Differences in Nutritional and Pharmacological Interventions.
    Gasperi V; Catani MV; Savini I
    Cardiovasc Ther; 2020; 2020():2342837. PubMed ID: 32547635
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gender and anti-thrombotic therapy: from biology to clinical implications.
    Marcucci R; Cioni G; Giusti B; Fatini C; Rossi L; Pazzi M; Abbate R
    J Cardiovasc Transl Res; 2014 Feb; 7(1):72-81. PubMed ID: 24469554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does pharmacotherapy improve cardiovascular outcomes in hemodialysis patients?
    Mittal M; Aggarwal K; Littrell RL; Agrawal H; Alpert MA
    Hemodial Int; 2015 Oct; 19 Suppl 3():S40-50. PubMed ID: 26448387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiplatelets and anticoagulants.
    Richard Conti C
    Clin Cardiol; 2010 Jul; 33(7):388-9. PubMed ID: 20641114
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of the Number of Anti-Thrombosis Agents in Hemodialysis Patients: BOREAS-HD2 Study.
    Tanaka M; Moniwa N; Ohnishi H; Yamashita T; Koyama M; Gocho Y; Nishizawa K; Kimura Y; Sugawara H; Murakami S; Okazaki Y; Furuhashi M; Yoshida H; Miura T
    Kidney Blood Press Res; 2017; 42(3):553-564. PubMed ID: 28922656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease.
    Dempster DW; Rosenstock JL; Schwimmer JA; Panagopoulos G; DeVita MV; Michelis MF
    Clin Nephrol; 2005 Nov; 64(5):371-7. PubMed ID: 16312265
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-platelet and anti-coagulant therapy in peripheral arterial disease prior to surgical intervention.
    Harky A; Maskell P; Burgess M
    Vascular; 2019 Jun; 27(3):299-311. PubMed ID: 30539687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of ginsenosides on platelet aggregation and vascular intima in the treatment of cardiovascular diseases: From molecular mechanisms to clinical applications.
    Luo BY; Jiang JL; Fang YF; Yang F; Yin MD; Zhang BC; Zhao RR; Shao JW
    Pharmacol Res; 2020 Sep; 159():105031. PubMed ID: 32562816
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiplatelet therapies for the treatment of cardiovascular disease.
    Michelson AD
    Nat Rev Drug Discov; 2010 Feb; 9(2):154-69. PubMed ID: 20118963
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.